GPX2 and colorectal carcinoma: Emmink et al. (28) demonstrated that inhibition of GPX2 by the NRF2 pathway in human CRC cells makes these cells more susceptible to cell death and the action of antineoplastic agents, such as cisplatin, resulting in high levels of intracellular ROS and consequently apoptosis of these cells.